For these patients, cough isn’t just a symptom - it rules their day. Trevi Therapeutics is targeting triggers in the lung as well as cough’s neurological roots,” says CEO Jennifer Good.
Epigenetic silencing is emerging as one of biotech’s boldest bets, and nChroma Bio is racing to prove it in the clinic. ‘Functional cures have been elusive, but epigenetic silencers are uniquely suited to the biological challenge for hepatitis B patients,’ Jeff Walsh says.
Biology’s data problem isn’t scarcity, it’s structure. Genomenon is addressing it by converting millions of scientific papers into usable genomic intelligence. “If Google had gone to school to get a PhD in molecular biology, that's what Mastermind is,” says CEO Mike Klein.
BillionToOne’s CEO, Dr. Oguzhan Atay, argues that “we are approaching biological problems from physics-based principles,” a mindset driving the company’s rapid growth, long-term focus, and pursuit of ultra-sensitive cancer and prenatal testing.
As regulators, pharma, and researchers search for more predictive tools, Emulate, Inc’s CEO, Jim Corbett, argues that Organ-on-a-Chip technology is still early. “If this were a nine-inning baseball game, we’re in the first inning - but the direction is very clear.”
“We’re really on the precipice of moving the company into that next stage of maturity,” Dr. Mike Exton
Driven by the precision of viral biology, 4D Molecular Therapeutics is redefining gene therapy’s reach - scaling a once ultra-rare field into broad, sustainable markets.
“Over the past year, we have made tremendous progress…” Rick Modi says, as Affinia Therapeutics pushes its BAG3-DCM program toward first-in-human testing, aiming to prove that next-generation capsids can restore heart function at dramatically lower doses.
“We can regulate any gene, anywhere,” says CEO Dr. Amber Salzman, whose Epicrispr team is pioneering epigenetic editing - a precise, non-cutting approach - to transform neuromuscular disease treatment through durable, targeted control of gene activity.
With a median progression-free survival nearing four years in ROS1 lung cancer, Nuvation Bio’s breakthrough therapy signals a turning point for precision oncology - validating Dr. David Hung’s patient-first vision.
Backed by $70 million in Series A funding, Excellergy emerges from stealth with a mission to lead a new era in immunology - targeting the full IgE pathway to redefine how allergic diseases are treated.
“Fifteen to twenty years ago, a woman under 35 had a 20% chance of live birth per IVF cycle. At Kindbody, today, it’s greater than 50%,” David Stern credits lab innovation and AI for rewriting fertility’s odds.
“After just one single infusion, about a third of patients remained in remission for five years. Some physicians even called it a functional cure,” Ying Huang underlines why CARVYKTI is reshaping expectations in oncology.
"We’re hunting for the twelve entrepreneurs that will save the world - the 12 instigators,” Khosla Ventures' Rajesh Swaminathan highlights the firm’s disciplined focus on breakthrough founders and bold science.
FLIM LABS is redesigning the tools of fluorescence-lifetime imaging to enable broader access across medicine, pharma, and environmental science.
Peter DeYoung lends insights on the strategic approach behind Piramal Phama’s expansion and growth.
